NO942641L - Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav - Google Patents

Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Info

Publication number
NO942641L
NO942641L NO942641A NO942641A NO942641L NO 942641 L NO942641 L NO 942641L NO 942641 A NO942641 A NO 942641A NO 942641 A NO942641 A NO 942641A NO 942641 L NO942641 L NO 942641L
Authority
NO
Norway
Prior art keywords
phosphatidylinositol
kinase
wortmannin
inhibition
analogs
Prior art date
Application number
NO942641A
Other languages
English (en)
Other versions
NO942641D0 (no
Inventor
Rosanne Bonjouklian
Garth Powis
Chris John Vlahos
Original Assignee
Lilly Co Eli
Arizona Board Of Regents The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Arizona Board Of Regents The filed Critical Lilly Co Eli
Publication of NO942641D0 publication Critical patent/NO942641D0/no
Publication of NO942641L publication Critical patent/NO942641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Wortmannin og visse analoger derav er inhibitorer av fosfatidylinositol 3-kinase. Forbindelsene er spesielt nyttige for inhibering av fosfatidylinositol 3-kinase i pattedyr og for behandling av fosfatidylinositol 3-kinase-avehengige tilstander, spesielt neoplasmer, i pattedyr.
NO942641A 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav NO942641L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (2)

Publication Number Publication Date
NO942641D0 NO942641D0 (no) 1994-07-14
NO942641L true NO942641L (no) 1995-01-20

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942641A NO942641L (no) 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Country Status (16)

Country Link
US (1) US5378725A (no)
EP (1) EP0635268A1 (no)
JP (1) JPH0753370A (no)
KR (1) KR950002755A (no)
CN (1) CN1111127A (no)
AU (1) AU678831B2 (no)
CA (1) CA2128046A1 (no)
CZ (1) CZ283806B6 (no)
HU (1) HUT67667A (no)
IL (1) IL110325A0 (no)
NO (1) NO942641L (no)
PH (1) PH30794A (no)
PL (1) PL304317A1 (no)
RU (1) RU94026082A (no)
TW (1) TW287102B (no)
ZA (1) ZA945103B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
JP4974408B2 (ja) * 1998-03-24 2012-07-11 中外製薬株式会社 血管形成抑制剤
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
CA2344653A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU6513701A (en) * 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078917A2 (en) * 2003-03-07 2004-09-16 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of pi 3-kinase
TW200503737A (en) * 2003-04-23 2005-02-01 Wyeth Corp Water soluble wortmannin derivatives
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
JP4777887B2 (ja) * 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
MXPA06001599A (es) 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
US7666901B2 (en) * 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
CN101115747A (zh) 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US20090305236A1 (en) * 2005-05-11 2009-12-10 Genetic Technologies Limited Methods of enriching fetal cells
US20090306020A1 (en) * 2005-05-27 2009-12-10 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20080199441A1 (en) * 2006-11-09 2008-08-21 Tony Peled Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010057048A1 (en) 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
KR20120005523A (ko) * 2009-04-20 2012-01-16 길리아드 칼리스토가 엘엘씨 고형 종양의 치료 방법
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
SG11201404608WA (en) 2012-02-13 2014-09-26 Gamida Cell Ltd Mesenchymal stem cells conditioned medium and methods of generating and using the same
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
KR20170012560A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
CZ283806B6 (cs) 1998-06-17
HU9402128D0 (en) 1994-09-28
PH30794A (en) 1997-10-17
IL110325A0 (en) 1994-10-21
JPH0753370A (ja) 1995-02-28
HUT67667A (en) 1995-04-28
AU6754094A (en) 1995-01-27
AU678831B2 (en) 1997-06-12
TW287102B (no) 1996-10-01
NO942641D0 (no) 1994-07-14
RU94026082A (ru) 1996-05-20
CA2128046A1 (en) 1995-01-20
PL304317A1 (en) 1995-01-23
CN1111127A (zh) 1995-11-08
US5378725A (en) 1995-01-03
CZ169294A3 (en) 1995-02-15
EP0635268A1 (en) 1995-01-25
ZA945103B (en) 1996-03-27
KR950002755A (ko) 1995-02-16

Similar Documents

Publication Publication Date Title
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
DE68915900D1 (de) Angiogenese hemmendes Mittel.
GR3024850T3 (en) Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
GR3021420T3 (en) 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
DE69516866D1 (de) Stereochemische wortmanninderivate
ES8801204A1 (es) Un procedimiento para la preparacion de derivados de indol
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ATE164593T1 (de) Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
ATE25682T1 (de) Indol-3-carboxamid-derivate.
DE69102936D1 (de) Bis(alkyl-substituierte-4-hydroxyphenylthio)alkan-Analoga als Inhibitoren der Kataraktentstehung.
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NO891703D0 (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
AU558461B2 (en) Carbamyloxybenzhyrol derivatives
EP0521080A4 (en) Synergistic compositions
IL89901A (en) Strobilurine derivative
AR005866A1 (es) Composicion farmaceutica antioxidante
FI932650A (fi) Foer skoetsel av B-cellers malignitet avsedda farmaceutiska blandningar